ObjectiveTo investigate the application value of argatroban in the treatment of ischemic stroke beyond thrombolysis time window.

MethodsEighty-six patients with ischemic stroke beyond thrombolysis time window were selected, and randomly divided into the control group (n=46) and observation group (n=40).The patients in the control group were treated with routine antithrombotic therapy, the patients with minor stroke were treated with aspirin combined with clopidogrel, and the treatment was changed to aspirin after 21 days, while patients with non-minor stroke were treated with aspirin.The patients in the observation group were treated with argatroban combined with aspirin.The National Institutes of Health stroke scale (NIHSS) score and the modified Rankin scale (mRS) score were compared between the two groups.

ResultsThe NIHSS scores in the observation group on the day of discharge and one month after discharge were lower than those in the control group (P < 0.05);the NIHSS scores in the observation group decreased gradually on the day of admission, the day of discharge and one month after discharge (P < 0.05);the difference of NIHSS scores in the control group among the day of admission, the day of discharge and one month after discharge was not statistically significant (P>0.05).The mRS scores in the observation group on the day of discharge and one month after discharge were lower than those in the control group (P < 0.05);the mRS scores in the observation group decreased gradually on the day of admission, the day of discharge and one month after discharge (P < 0.05);the difference of mRS scores in the control group among the day of admission, the day of discharge and one month after discharge was not statistically significant(P>0.05).

ConclusionsArgatroban is effective in the treatment of ischemic stroke beyond thrombolytic time window, is beneficial to improve the prognosis of patients, and has good safety.